logo
Why congressional stock-trade ban efforts are about to heat up

Why congressional stock-trade ban efforts are about to heat up

Get ready to hear a lot more about banning congressional stock trading.
A top Trump administration official says he's going to start pushing for a ban. Two House Republicans are, in different ways, gearing up to force a vote on the issue. And all the while, lawmakers keep failing to report millions of dollars' worth of stock trades on time.
"We've got to move," Republican Rep. Chip Roy of Texas said on Fox Business earlier this month, saying that while he had given House GOP leadership "grace" as they worked to get the "Big Beautiful Bill" through Congress, that time is now over. "I'm going to demand that we vote on this, this fall."
It all comes after an explosive Senate hearing on a stock trading bill last month, where Republicans went after one another over whether President Donald Trump himself should be banned from trading stocks.
That led to Trump branding Sen. Josh Hawley as "second-tier," though the Missouri Republican later told BI that he was able to smooth things over with Trump later.
"He told me he wants a stock trading ban," Hawley said in July. "He remains committed to getting a stock trading ban, so we'll work with him to do that."
Potential House drama over a 'discharge petition'
Rep. Anna Paulina Luna, a Florida Republican known for challenging her own party's leadership, has said she'll start the process of forcing a vote on a stock trading ban when lawmakers return from the August recess.
"I won't sit idly by while members of Congress trade stocks, especially those on committees with direct influence over relevant industries," Luna wrote on X last month. "That's corruption at its core, and it needs to stop."
Luna has said she'll try to use what's known as a "discharge petition" to bring up a stock trading ban bill authored by Republican Rep. Tim Burchett of Tennessee.
Under that process, the bill would have to be brought to the House floor for a vote — with or without the support of House leaders — if Luna is able to collect signatures from 218 members, a majority of the 435 seats in the House.
Not everyone who supports a stock trading ban is on board with Luna's approach. Roy, the co-sponsor of a different stock trading ban bill that has bipartisan support and has been around for years, told Fox Business that a discharge petition is "not the best way" to get it done.
"I want the speaker, and Republicans, to control this," said Roy. "Republicans need to control the floor, do our job, bring this to a vote."
Roy has been working with a bipartisan group that includes Democratic Reps. Seth Magaziner of Rhode Island and Alexandria Ocasio-Cortez of New York to put forward a consensus stock trading ban bill.
But after months of discussions, they have yet to release legislative text. That's led Luna to largely dismiss their effort.
"Allegedly, there were 'talks' happening? With who?" Luna wrote on X on Thursday. "They were never going to bring a VOTE to the floor. I don't care if this upsets people."
The Florida congresswoman's effort is worth taking seriously: she has used this legislative tool before to bring up a bill on proxy voting over the objections of Speaker Mike Johnson, bringing the House to a halt for a full week in April.
Lawmakers keep reporting trades late
Johnson has said he's supportive of a stock trading ban — though he has "sympathy" for arguments against it. House Minority Leader Hakeem Jeffries began forcefully supporting it this year in the wake of well-timed tariff trades by some lawmakers.
Even Trump has backed it, though some Republicans are wary of applying the bill's restrictions to him.
This week, Treasury Secretary Scott Bessent got in on the action, saying he himself would begin pushing for a ban on lawmakers trading individual stocks.
"I don't think we have the perfect bill yet," Bessent told Bloomberg this week. "But I am going to start pushing for a single-stock trading ban."
Meanwhile, several lawmakers in have been found in violation of the STOCK Act in recent weeks, disclosing millions of dollars worth of trades long after the 30-45 day deadline for doing so.
Rep. Lisa McClain of Michigan, the fourth-highest ranking House Republican, was late to disclose over 500 trades made by her husband from March 2024 through June 2025, totalling at least $1.5 million. Republican Rep. Dan Meuser of Pennsylvania failed to disclose that his wife sold between $750,000 and $1.5 million in NVIDIA stock last year. And Sen. Markwayne Mullin of Oklahoma was late in disclosing millions of dollars made by him and his wife since 2023.
Lawmakers are only required to disclose asset ranges on their reports, so we don't know the exact value of the trades.
Those lawmakers and their spokespeople blamed errors made by third-party financial managers and lack of awareness of the trades for the late disclosures.
A spokesperson for McClain told BI that the congresswoman "promptly filed the necessary paperwork immediately after being made aware of the transactions made in managed accounts and remains committed to transparency and adherence to all House financial disclosure rules and regulations."
"I take compliance with all House rules seriously and expect the same from those managing my accounts," Meuser told BI through a spokesperson. "This was a simple, automatic filing that should have occurred without error. The mistake was made solely by my brokerage and benefited me in no way."
Mullin's office did not respond to BI's request for comment, but a spokesperson told NOTUS that the senator doesn't trade himself, but relies on a third-party broker.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts
Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts

Yahoo

time22 minutes ago

  • Yahoo

Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts

Relay Therapeutics Inc. (NASDAQ:RLAY) is one of the most promising penny stocks under $5. On August 8, Raymond James lowered the firm's price target on Relay Therapeutics to $19 from $29, while keeping a Strong Buy rating on the shares. This sentiment followed Relay Therapeutics' Q2 2025 results, where OpEx was down 16% sequentially following strategic cost-cutting initiatives. Relay Therapeutics reported a net loss of $70.4 million, or $0.41 per share, in Q2 2025, which was an improvement compared to the net loss of $92.2 million, or $0.69 per share, in Q2 2024. Revenue for the quarter was $0.7 million, which was an increase from zero revenue in the same period last year. A chemist arranging containers of compounds, ready for the commercialization process. This quarter also featured the initiation of the Phase 3 ReDiscover-2 trial for RLY-2608 in Q2 2025. At the 2025 American Society for Clinical Oncology/ASCO Annual Meeting, updated interim data from the Phase 1b study for RLY-2608 were presented. In addition to oncology, Relay Therapeutics is continuing to execute its ongoing Phase 1 clinical trial for vascular malformations. Relay Therapeutics Inc. (NASDAQ:RLAY) is a clinical-stage precision medicines company that transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. While we acknowledge the potential of RLAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Canaccord Lowers Clover Health (CLOV) PT to $4.10 Despite Strong Q2 Growth
Canaccord Lowers Clover Health (CLOV) PT to $4.10 Despite Strong Q2 Growth

Yahoo

time22 minutes ago

  • Yahoo

Canaccord Lowers Clover Health (CLOV) PT to $4.10 Despite Strong Q2 Growth

Clover Health Investments Corp. (NASDAQ:CLOV) is one of the most promising penny stocks under $5. On August 7, Canaccord lowered the firm's price target on Clover Health to $4.10 from $4.50, while keeping a Buy rating on the shares. The firm said the company reported solid Q2 2025 results, but the insurance benefit expense ratio came in higher than expected, which was of some concern. In Q2, the company's Medicare Advantage membership grew by over 30% year-over-year, and the insurance revenue increased by 34% to $470 million. Clover Health Investments' technology-first care model, which includes the Clover Assistant platform, showed a 15% reduction in hospitalizations and an 18% reduction in readmissions for patients with chronic obstructive pulmonary disease/COPD. An older Medicare-eligible consumer smiling happily while receiving healthcare services at a clinic. The company is now well-positioned for future growth with a 4-star payment year in 2026, which is expected to provide a financial tailwind. Clover Health is also expanding its technology platform to other risk-bearing entities, potentially opening up additional revenue streams. Clover Health Investments Corp. (NASDAQ:CLOV) is a company that provides medicare advantage plans in the US. It operates Clover Assistant, which is a software platform to execute strategy by enabling physicians to detect, identify, and manage chronic diseases earlier than they otherwise could. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

RBC Capital Cuts Algoma Steel (ASTL) PT to C$8 Following Q2 Net Loss
RBC Capital Cuts Algoma Steel (ASTL) PT to C$8 Following Q2 Net Loss

Yahoo

time22 minutes ago

  • Yahoo

RBC Capital Cuts Algoma Steel (ASTL) PT to C$8 Following Q2 Net Loss

Algoma Steel Group Inc. (NASDAQ:ASTL) is one of the most promising penny stocks under $5. On July 31, RBC Capital lowered the firm's price target on Algoma Steel to C$8 from C$10, while maintaining a Sector Perform rating on the shares. Prior to this decision, the company released its Q2 2025 earnings. Algoma Steel Group reported a net loss of $110.6 million, which was a sharp contrast to the net income of $6.1 million in the prior year's quarter. Adjusted EBITDA was a loss of $32.4 million, which reflected a negative margin of 5.5%. This was driven by a 10.5% year-over-year decline in steel revenue to $534 million, as well as lower steel shipments of 472,000 net tons, down 6.2% from the previous year. A factory worker operating a machine that processes steel products. The average net sales realization was $1,132 per ton, a decrease from $1,187 per ton in the prior year period, while the average cost per ton of steel products sold increased by 7% year-over-year to $1,144. A major factor contributing to the financial downturn was $64 million in direct tariff costs on outbound steel shipments to the US, which is a market now effectively closed to Canadian steel producers due to prohibitive tariffs. The company also reported ending the quarter with inventories valued at $736 million, a decrease from $800 million in the prior year quarter. Algoma Steel Group Inc. (NASDAQ:ASTL) produces and sells steel products in Canada, the US, and internationally. While we acknowledge the potential of ASTL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store